• Médecine sciences : M/S · Mar 2012

    Review

    [Genomics and clinical research for breast cancer].

    • François Bertucci and Daniel Birnbaum.
    • Département d'oncologie médicale, Institut Paoli-Calmettes, centre de recherche en cancérologie de Marseille, France. bertuccif@marseille.fnclcc.fr
    • Med Sci (Paris). 2012 Mar 1; 28 Spec No 1: 14-8.

    AbstractGenomics of breast cancer is paving the way towards more and more tailored treatments. The number of molecularly targeted therapies under development is increasing. In parallel, the high-throughput analyses revealed the molecular heterogeneity of disease, and identified several very different molecular subtypes, numerous and sometimes very scarce molecular alterations, and multigenic signatures predictive for clinical outcome, some of which are being tested in prospective clinical trials. This molecular segmentation of breast cancer and the multitude of new drugs to be tested (alone and in combination) lead to develop clinical trials based on the molecular profile of tumors to guide the patient towards the most suitable drug.© 2012 médecine/sciences – Inserm / SRMS.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…